RXRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Recursion Pharmaceuticals Inc (RXRX) is not a strong buy for a beginner investor with a long-term focus at this time. The stock is currently in a bearish trend with limited positive catalysts, and the financial performance shows significant losses despite revenue growth. Analysts have mixed views, and there is no strong proprietary trading signal to suggest immediate action. Holding off on this investment until more favorable conditions emerge would be prudent.
The stock is in a bearish trend with SMA_200 > SMA_20 > SMA_5. The RSI is neutral at 36.366, and the MACD is slightly positive but contracting. Key support is at 3.382, and resistance is at 3.955. The stock is trading below its pivot point of 3.669, indicating downward pressure.
The company's REC-4881 has shown strong efficacy in familial adenomatous polyposis, with a broader addressable market and potential peak sales over $1B. JPMorgan has upgraded the stock to Overweight, citing promising developments in REC-617 for ovarian cancer. Revenue has increased significantly YoY.
The stock has a bearish trend and is down -3.24% in the regular market. Analysts have lowered price targets due to delays in the REC-617 launch. Financial performance shows a significant net income loss (-39.56% YoY) and declining EPS (-60.38% YoY). Gross margin has dropped significantly (-132.98% YoY). No recent congress trading data or strong hedge fund/insider activity.
In Q4 2025, revenue increased by 681.74% YoY to $35.54M. However, net income dropped to -$108.12M (-39.56% YoY), EPS declined to -0.21 (-60.38% YoY), and gross margin fell to 59.83 (-132.98% YoY). The company is still operating at a loss despite revenue growth.
Mixed. JPMorgan upgraded the stock to Overweight with a price target of $11, citing strong efficacy and market potential for REC-4881. However, BofA lowered its price target to $6 from $7 and maintained a Neutral rating due to delays in the REC-617 launch and revised estimates.
